Collectively, these findings suggest that CALR and CTSB can be used as effective biomarkers for CLN6 disease, whereas APOE, CTSZ and HEXA might serve as effective biomarkers for multiple NCL subtypes. This evidence concerns the gene CTSB and CLN6 disease.